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Between 1984 and 2006, 12959 people with HIV/AIDS (PWHA) in the Swiss HIV Cohort Study contributed a total of 73412
person-years (py) of follow-up, 35551 of which derived from PWHA treated with highly active antiretroviral therapy (HAART). Five
hundred and ninety-seven incident Kaposi sarcoma (KS) cases were identified of whom 52 were among HAART users. Cox
regression was used to estimate hazard ratios (HR) and corresponding 95% confidence intervals (CI). Kaposi sarcoma incidence fell
abruptly in 1996–1998 to reach a plateau at 1.4 per 1000py afterwards. Men having sex with men and birth in Africa or the Middle
East were associated with KS in both non-users and users of HAART but the risk pattern by CD4 cell count differed. Only very low
CD4 cell count (o50 cellsml
 1) at enrolment or at HAART initiation were significantly associated with KS among HAART users. The
HR for KS declined steeply in the first months after HAART initiation and continued to be low 7–10 years afterwards (HR, 0.06; 95%
CI, 0.02–0.17). Thirty-three out of 52 (63.5%) KS cases among HAART users arose among PWHA who had stopped treatment or
used HAART for less than 6 months.
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At the beginning of the HIV epidemic, Kaposi sarcoma (KS) was
one of the most common manifestations of AIDS (Dal Maso et al,
1995; Biggar et al, 1996), present during the mid-1980s in 25% of
individuals at the time of AIDS diagnosis in the United States, but
decreased steadily through the late 1980s and mid-1990s, down to
2% after the advent and widespread use of highly active
antiretroviral therapy (HAART) in 1996 (Engels et al, 2006).
A similar temporal pattern was observed for KS in Australia
(Grulich et al, 2001) and in European countries (Dal Maso et al,
1995; Rezza et al, 2000; Franceschi et al, 2003; Mocroft et al, 2004;
Clifford et al, 2005), but detailed data on the long-term trends of
KS incidence in Europe are limited. We therefore took advantage
of the more than 20 years of follow-up data available from the
Swiss HIV Cohort Study (SHCS) to assess changes in the incidence
of and risk factors for KS before and after HAART use.
MATERIALS AND METHODS
The SHCS is an ongoing study that has been enrolling people with
HIV/AIDS (PWHA) over 16 years of age since 1988, with some
retrospective enrolment going back to 1984, from seven large
hospitals in Swiss cities (Basel, Bern, Geneva, Lausanne, Lugano, St
Gallen, and Zurich) (www.shcs.ch). Follow-up visits take place
every 6 months and all AIDS-defining events, including KS
diagnosis and death, are recorded. The present study included
PWHA enrolled up to 30 September 2005, and information
recorded in the SHCS database up to 31 March 2006. People with
HIV/AIDS were excluded from the present study if they (1) did not
have information on date of birth, gender, or HIV transmission
category (number (n)¼54), (2) were diagnosed with KS at
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yenrolment or earlier (n¼368), or (3) had no follow-up visits
(n¼131).
A total of 597 KS cases were included in our present study: 545
were identified from the SHCS database, and 52 through record
linkage with eight Swiss Cantonal Cancer Registries (Clifford et al,
2005). Six of these cancer registries (Basel, Geneva, Ticino,
St Gallen and Appenzell, Vaud, and Zurich) overlap directly with
six of the seven cantons covered by SHCS hospitals (all except
Bern). The Neucha ˆtel and Valais Cancer Registries do not directly
overlap with SHCS hospitals, but some residents of these cantons
are followed in a neighbouring SHCS hospital. Places of birth were
classified as Europe (Switzerland and the rest of Europe, 87.1% of
PWHA) and Africa or the Middle East (8.1%). The few SHCS
participants born outside Europe, but in countries where KS is not
endemic (e.g., the Americas and Asia; Hengge et al, 2002), were
included in the Europe category. Conversely, the few PWHA born
in the Caribbean were included in the Africa/Middle East category.
Histological confirmation was mentioned in the majority of KS
cases, but presentation site (i.e., skin only vs other) was available
only for 382 (64%) KS cases.
Highly active antiretroviral therapy was defined as a combina-
tion of at least three drugs, including a protease inhibitor or a non-
nucleoside transcriptase inhibitor, or three nucleosides including
abacavir. Individuals who had used HAART for more than
1 month were classified as users. Treatment interruption was
defined as in a previous report from the SHCS (Taffe ´ et al, 2002),
as absence of any antiretroviral drug in PWHA who were
previously receiving HAART. Taffe ´ et al (2002) evaluated the
impact of interruptions of less than 3 months on the progression of
HIV infection, whereas we focused on the impact of interruptions
of 3 months or more on KS incidence. CD4 cell counts at
enrolment in the SHCS and, among HAART users, at, or within
6 months before HAART initiation were retrieved.
For each participant, person-years (py) at risk were calculated
between enrolment and KS diagnosis, death, or last follow-up visit,
whichever occurred first. Incidence rates per 1000py were
standardised for gender and age based on the enrolled population
in the overall study period, using the direct method (Breslow and
Day, 1987). Ninety-five percent confidence intervals (CI) of
incidence were computed according to the Poisson distribution
(Breslow and Day, 1987). The effect of various risk factors on KS
onset was assessed using hazard ratios (HR) and corresponding
95% CI, estimated by means of the Cox proportional hazard model
(Cox, 1972), and adjusted for SHCS centre, gender, age (in 5-year
groups), HIV transmission category (MSM and non-MSM)
and, when mentioned, CD4 cell count at enrolment or at HAART
initiation (o50, 50–99, 100–199, 200–349, X350 cellsml
 1, and
unknown). Calendar period, HAART use, and months after
HAART initiation and after treatment interruption were intro-
duced as time-dependent variables.
This study was approved by the local ethics committees of the
collaborating SHCS clinics and of the International Agency for
Research on Cancer.
RESULTS
The present study included 12638 PWHA who were KS-free at
enrolment and among whom 597 incident KS cases were identified
(8.2 per 1000py; 95% CI, 7.6–8.9). Fifteen per cent of PWHA had
AIDS at enrolment and an additional 3119 (24.7%) developed it
during follow-up. Among the latter, KS was the AIDS-defining
illness in 268, whereas 329 KS cases developed in PWHA who had
already manifested another AIDS-defining illness.
Figure 1 shows KS temporal trends: overall KS incidence was
33.3 per 1000py in 1984–1986 and did not change significantly in
the subsequent periods until 1996–1998, when it fell to 5.1 (95%
CI, 3.9–6.5) per 1000py. Kaposi sarcoma incidence further
decreased to 1.4 per 1000py in 1999–2001 and remained constant
thereafter. Temporal trends in KS incidence were chiefly driven by
men having sex with men (MSM), but they were consistent among
other HIV transmission categories (Figure 1).
A large proportion (48.4%) of available py derived from HAART
users and Table 1 shows the incidence and HR of KS by various
characteristics separately among non-users and users of HAART.
Incidence of KS decreased from 15.0 per 1000py in non-users to
1.3 per 1000py in users (HR, 0.11; 95% CI, 0.08–0.14). Among
non-users of HAART, intravenous drug users (HR, 0.09; 95% CI,
0.06–0.13), and heterosexuals and other HIV transmission
categories (HR, 0.27; 95% CI, 0.20–0.36) showed a lower KS
incidence than MSM. The HR for KS was increased among PWHA
older than 35 years (HR, 1.53; 95% CI, 1.29–1.82) and those born
in Africa/Middle East (HR, 1.84; 95% CI, 1.10–3.06). Kaposi
sarcoma risks among non-users of HAART steeply increased with
decreasing CD4 cell count (HR for o50 vs X350 cellsml
 1, 12.85;
95% CI, 9.59–17.23). These associations were also present, but
were weaker, among HAART users with the exception of the
association with place of birth that became stronger (HR for
Africa/Middle East vs Europe among HAART users, 6.49; 95% CI,
2.79–15.11). In contrast with non-users, no change in the HR for
KS was seen among HAART users with CD4 cell counts in the
range of 50–X350 cellsml
 1 and the only significant risk increase
was found for CD4 cell count less than 50 cellsml
 1 at enrolment
(HR, 3.26; 95% CI, 1.53–6.91). On account of the rarity of KS
among HAART users, HRs showed, however, broad CIs (Table 1).
Among HAART users, CD4 cell count at treatment initiation
below 50 cellsml
 1 (HR vs X350 cellsml
 1, 5.36; 95% CI, 2.08–
13.80) (data not shown) was even more strongly associated with KS
risk than CD4 cell count at enrolment. Furthermore, KS risk was
greatly increased among PWHA who had stopped using any
antiretroviral drugs for at least 3 months (HR, 8.14; 95% CI, 4.01–
16.54) (Table 1). Additional adjustment for CD4 cell count at
HAART initiation did not modify the HR for treatment interrup-
tion (HR, 9.45; 95% CI, 4.64–19.25, data not shown).
Skin was reported as the presentation site in the majority of KS
cases (74.3%). Temporal trends and associations with HAART use
and CD4 cell count (overall and in separate strata by HAART use)
did not differ by KS presentation site (data not shown).
Figure 2 shows the HR for KS in different periods after HAART
initiation compared with non-users. The HR of KS was already
reduced by 76% in the first 5 months of use and declined to 0.06
(95% CI, 0.02–0.17) in the subsequent 6 months of use. The
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Figure 1 Incidence rates of KS by calendar period, overall and according
to HIV transmission category. Rates were standardised (direct method) on
age and gender, based on Swiss HIV Cohort Study participants. Vertical
bars represent 95% CI. MSM: men having sex with men.
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after HAART initiation (HR, 0.06; 95% CI, 0.02–0.16) (Figure 2).
Finally, the 52 HAART users who developed KS were
individually reviewed and classified into the following groups:
(1) no antiretroviral drug in the 3 months before KS diagnosis;
(2) recent initiation of HAART (o6 months before KS diagnosis);
(3) severe immunodeficiency (CD4 cell count o100 cellsml
 1 at KS
onset while on HAART for X6 months); and (4) none of the above
(data not shown). Eighteen (34.6%) KS cases had not been taking
any antiretroviral drug for 3 months or more, and in 10 instances
for 12 months or longer. Recent initiation of HAART was
identified in 15 KS cases, among whom five of the nine KS were
from Africa/Middle East. Severe immunodeficiency was identified
among 10 KS cases. Nine KS cases, all from the MSM transmission
category, could not be assigned to any of the three categories
above. Five of them (aged 35, 49, 52, 56, and 63 years) had a CD4
cell count X400 cellsml
 1 (i.e., 405, 440, 557, 596, 782) at KS
diagnosis.
DISCUSSION
Our study shows the dramatic decline of KS incidence in the SHCS
following the advent of HAART. This expands an earlier report
(Ledergerber et al, 1999) from this cohort showing that by 1998 the
KS decline was at least as large as that seen for opportunistic
infections. Similar reductions in the incidence of KS among PWHA
were seen in many other studies (International Collaboration on
HIV and Cancer, 2000) although the decrease started earlier (i.e.,
even before the introduction of HAART) in the United States
(Biggar et al, 1996; Engels et al, 2006) and Australia (Grulich et al,
2001) than in Europe (Dal Maso et al, 1995). The prevalence of KS
herpesvirus, the cause of KS (IARC, 1997), may have been
especially high in the first wave of HIV infection in MSM in the
United States and Australia (Osmond et al, 2002).
Highly active antiretroviral therapy became rapidly available to
SHCS participants and, by 1997, 80% of them were using three
antiretroviral drugs or more (www.shcs.ch). The proportion
of SHCS participants with CD4 cell counts o350 cellsml
 1 who
had never been treated was small (o3%) in 2006 in all HIV
transmission categories. Despite the widespread use of HAART
and the introduction after 1996 of successively more potent
Table 1 Incidence rates and HR of KS overall and by selected characteristics, and use of HAART
HAART non-users
a HAART users
KS py Incidence/1000py (95% CI)
b HR (95% CI)
c KS py Incidence/1000py (95% CI)
b HR (95% CI)
c
Overall 545 37861 15.0 (13.8–16.3) 1
d 52 35551 1.3 (1.0–1.7) 0.11 (0.08–0.14)
HIV transmission category
MSM
d 446 10900 27.8 (25.3–30.5) 1 35 12216 1.6 (1.1–2.3) 1
Het/Oth 62 10183 8.9 (6.8–11.4) 0.27 (0.20–0.36) 16 13796 1.2 (0.7–1.9) 0.54 (0.27–1.10)
IDU 37 16778 2.1 (1.5–2.9) 0.09 (0.06–0.13) 1 9539 0.0 (0.0–0.3) 0.05 (0.01–0.37)
Age at enrolment (years)
o35
d 256 27795 7.4 (6.5–8.4) 1 25 20136 0.9 (0.6–1.3) 1
X35 289 10066 17.6 (15.7–19.8) 1.53 (1.29–1.82) 27 15416 1.4 (1.0–2.1) 1.07 (0.61–1.85)
Place of birth
Europe
d 529 36334 15.0 (13.8–16.4) 1 43 32495 1.0 (0.7–1.4) 1
Africa/Middle East 16 1527 12.5 (7.1–20.4) 1.84 (1.10–3.06) 9 3057 2.4 (1.1–4.6) 6.49 (2.79–15.11)
CD4 cell count at enrolment (cellsml
 1)
X350
d 128 20988 6.7 (5.6–8.0) 1 18 15212 1.0 (0.6–1.6) 1
200–349 93 6126 15.3 (12.4–18.8) 2.44 (1.86–3.20) 9 8382 0.9 (0.4–1.8) 0.84 (0.38–1.88)
50–199 133 3883 33.6 (28.2–39.9) 5.04 (3.90–6.51) 11 7556 1.1 (0.6–2.0) 1.13 (0.53–2.44)
o50 94 1119 77.1 (62.3–94.3) 12.85 (9.59–17.23) 12 3021 4.8 (2.5–8.4) 3.26 (1.53–6.91)
Unknown 97 5745 18.1 (14.7–22.1) — 2 1381 0.7 (0.1–2.7) —
Treatment interruption
e
No
d — — — — 28 27234 0.9 (0.6–1.2) 1
Yes — — — — 24 8317 2.8 (1.8–4.1) 8.14 (4.01–16.54)
CI¼confidence interval; HAART¼highly active antiretroviral therapy; Het/Oth¼heterosexuals and other; HR¼hazard ratio; IDU¼intravenous drug users; KS¼Kaposi
sarcoma; MSM¼men having sex with men; py¼person-years.
aIndividuals who were never treated with HAART and py before HAART among HAART users.
bRates are
standardised (direct method) on age and/or gender based on all SHCS participants.
cAdjusted for centre, age, gender, and HIV transmission category, when appropriate.
dReference category.
eAbsence of any antiretroviral drug for X3 months.
Months after HAART initiation
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Figure 2 Hazard ratio of Kaposi sarcoma in patients receiving highly
active antiretroviral therapy (HAART) following treatment initiation.
Adjusted for centre, age, gender, HIV transmission category (men having
sex with men, other), and CD4 cell count at enrolment. Vertical bars
represent 95% confidence intervals. Reference category was defined as
non-users of HAART.
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reached a plateau after 2001, as reported among AIDS patients in
the United States (Engels et al, 2006).
In addition to making KS a relatively rare event, HAART use has
also diminished the variation in KS risk by host characteristics,
including gender, age group, and to some extent, HIV transmission
category and CD4 cell count at enrolment as compared with
that found among non-users. Only a count o50 cellsml
 1 at
enrolment or HAART initiation was associated with an increased
HR for KS. Reduced importance of CD4 cell count at enrolment in
HAART users vs non-users was also seen in the SHCS for
non-Hodgkin’s lymphoma, but the impact of HAART on non-
Hodgkin’s lymphoma was weaker (HR, 0.26; 95% CI, 0.20–0.33)
than on KS, and, hence, non-Hodgkin’s lymphoma incidence (1.9;
95% CI, 1.6–2.6 per 1000py) became higher than KS incidence
among HAART users (Polesel et al, 2008).
Kaposi sarcoma risk was already reduced by over 90% after
1 year of HAART and it did not show any sign of increasing again
for at least 10 years. The decline of non-Hodgkin’s lymphoma risk
after HAART initiation was more gradual than for KS, but equally
prolonged (Polesel et al, 2008).
Approximately one-third of HAART users in the SHCS had one
or more interruptions of antiretroviral treatment (Taffe ´ et al, 2002)
due in most cases either to intolerance to drugs, or social factors
(i.e., being an intravenous drug user, poor education, etc.), and not
to treatment failure. In our study, the absence of any antiretroviral
treatment for 3 months or more was associated with an eight-fold
increased KS risk, thus confirming the danger of treatment
interruption already reported with respect to progression to AIDS
or death (Holkmann et al, 2007). Significantly higher KS incidence
among PWHA who were assigned to the CD4 cell-guided
intermittent antiretroviral treatment arm than those assigned to
the continuous treatment arm was also shown in a randomised
clinical trial (Silverberg et al, 2007).
Of the 52 KS among HAART users, 23 arose among people who
had either stopped using HAART at or had initiated treatment less
than 6 months before KS diagnosis. Recent initiation of HAART
in the SHCS seemed especially important among KS cases born in
Africa/Middle East, suggesting possible delays in the diagnosis or
treatment of HIV infection. Ten KS cases arose in PWHA whose
CD4 cell count was very low despite concurrent HAART use
whereas 5 MSM developed KS despite being on HAART and having
CD4 cell counts at which AIDS-related KS is seldom seen (Biggar
et al, 2007). The occurrence of KS cases in PWHA with high CD4
cell counts and undetectable viral loads has already been reported
in the United States after 1996 (Maurer et al, 2007; Krown et al,
2008). It is possible that, with the ageing of PWHA, those who are
co-infected with KS herpesvirus may develop KS despite good
control of HIV infection.
Weaknesses of our study are the lack of information on year of
HIV seroconversion and on the presence of KS herpesvirus co-
infection. Furthermore, we evaluated HAART use by intention-to-
treat, that is, without subtracting all periods where treatment had
been stopped, so its efficacy may be underestimated. A major
strength of our cohort study is that it is the largest ever reported
with respect to the number of KS cases and the number of person-
years of HAART use. Furthermore, the representativeness of the
SHCS with respect to Swiss PWHA was especially good (i.e.,
inclusion of 49% of all HIV-positive people and 67% of all AIDS
cases in the country, www.shcs.ch).
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